The present study aimed at evaluating the effect of gliclazide on cardiovascular risk factors involved in type 2 diabetes mellitus using n-STZ rat model on a long term basis. Methods: The diabetic model was developed using a split dose of streptozotocin (50 mg/kg) intraperitoneally on 2 nd and 3 rd postnatal days. The diabetic rats were treated orally with gliclazide suspension at the dose of 10 mg/kg for 90 days. Cardiovascular risk factors such as systolic blood pressure, heart rate, lipid

more »

... file, creatine kinase and lactate dehydrogenase were evaluated at regular intervals along with fasting blood glucose (FBG) and oral glucose tolerance test. Results: Gliclazide did not alter FBG however improved the impaired glucose tolerance. The gliclazide treated rats did not develop hypertension and there was a significant difference (p<0.001) at the end of treatment when compared to the diabetic group which could be due to free radical scavenging property of gliclazide. Gliclazide treatment in n-STZ model was found to be effective in preventing hypertension, creatine kinase and lactate dehydrogenase activity. Also gliclazide was found to have beneficial effects on the impaired glucose tolerance, dyslipidaemia, adiposity index and total fat pad weight. Conclusions: To improve and prevent the cardiovascular risk factors involved in Type II diabetic patients, gliclazide could be clinically beneficial.